These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27265561)

  • 1. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.
    Grosse SD; Thompson JD; Ding Y; Glass M
    Milbank Q; 2016 Jun; 94(2):366-91. PubMed ID: 27265561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State.
    Ding Y; Thompson JD; Kobrynski L; Ojodu J; Zarbalian G; Grosse SD
    J Pediatr; 2016 May; 172():127-35. PubMed ID: 26876279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policy issues related to expanded newborn screening: a review of three genetic/metabolic disorders.
    Bishop Hubbard H
    Policy Polit Nurs Pract; 2007 Aug; 8(3):201-9. PubMed ID: 18178927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
    Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
    J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study.
    Sims EJ; Mugford M; Clark A; Aitken D; McCormick J; Mehta G; Mehta A;
    Lancet; 2007 Apr; 369(9568):1187-95. PubMed ID: 17416263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
    Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
    Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.
    Insinga RP; Laessig RH; Hoffman GL
    J Pediatr; 2002 Oct; 141(4):524-31. PubMed ID: 12378192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A primer on economic evaluations related to expansion of newborn screening for genetic and metabolic disorders.
    Hubbard HB
    J Obstet Gynecol Neonatal Nurs; 2006; 35(6):692-9. PubMed ID: 17105633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.
    Grosse SD; Boyle CA; Botkin JR; Comeau AM; Kharrazi M; Rosenfeld M; Wilfond BS;
    MMWR Recomm Rep; 2004 Oct; 53(RR-13):1-36. PubMed ID: 15483524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A short-term diagnostic and economic impact model of neonatal screening for cystic fibrosis].
    Rasch A; Perleth M
    Klin Padiatr; 2011 Mar; 223(2):96-103. PubMed ID: 21305445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.
    Hamers FF; Rumeau-Pichon C
    BMC Pediatr; 2012 Jun; 12():60. PubMed ID: 22681855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis screening in newborns: results from existing programs.
    Young SS; Kharrazi M; Pearl M; Cunningham G
    Curr Opin Pulm Med; 2001 Nov; 7(6):427-33. PubMed ID: 11706321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Societal value of newborn screening for severe combined immune deficiency in Arkansas: An economic analysis.
    Hays LH
    Public Health Nurs; 2019 Jul; 36(4):541-544. PubMed ID: 30945355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands.
    van der Hilst CS; Derks TG; Reijngoud DJ; Smit GP; TenVergert EM
    J Pediatr; 2007 Aug; 151(2):115-20, 120.e1-3. PubMed ID: 17643759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of expanded newborn screening in Texas.
    Tiwana SK; Rascati KL; Park H
    Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of tandem mass spectrometry screening in California.
    Feuchtbaum L; Cunningham G
    Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.
    van der Ploeg CP; van den Akker-van Marle ME; Vernooij-van Langen AM; Elvers LH; Gille JJ; Verkerk PH; Dankert-Roelse JE;
    J Cyst Fibros; 2015 Mar; 14(2):194-202. PubMed ID: 25213034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.